TITLE

How long should a woman take raloxifene?

PUB. DATE
January 1998
SOURCE
HealthFacts;Jan98, Vol. 23 Issue 1, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Raises medical concerns regarding the long-term use of the designer estrogen drug raloxifene citing the experience with similar drug Tamoxifen as cause for concern. Background on Tamoxifen.
ACCESSION #
136368

 

Related Articles

  • Form of estrogen replacement therapy and blood pressure. Walling, Anne D. // American Family Physician;4/1/1997, Vol. 55 Issue 5, p1950 

    States that Akkad and colleagues studied the effect of both oral and transdermal estrogen on 24-hour ambulatory blood pressure. Method used in the study; Effects of estrogen replacement therapy in women; Conclusion.

  • Oral estrogen, but not patch, boosts clot risk with HRT.  // Contemporary OB/GYN;Apr2007, Vol. 52 Issue 4, p12 

    The article discusses research being done on the link between oral estrogen and the risk of venous thromboembolism (VTE) in postmenopausal women. It references a study by Pierre-Yves Scarabin and colleagues, published in the February 20, 2007 issue of "Circulation." The study compared the risk...

  • Estrogen Therapy and the Risk of Alzheimer's Disease. Nuovo, James // American Family Physician;1/15/1998, Vol. 57 Issue 2, p358 

    Presents a summary of the article `A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore longitudinal study of aging,' by C. Kawas, et al, published in a 1997 edition of `Neurology' periodical.

  • Is Benign Breast Disease a Contraindication for ERT? Miller, Karl // American Family Physician;8/1/1999, Vol. 60 Issue 2, p615 

    Highlights a study of women with benign breast disease established by biopsy to identify a possible link between estrogen replacement therapy and breast cancer risk. Materials; Methodology; Results; Conclusion; Implications.

  • Hypercoagulability from low-dose estrogen? H.D.B. // Cortlandt Forum;3/25/96, Vol. 9 Issue 3, p109 

    Discusses the potential risk of hypercoagulability in a woman with deep venous thrombosis and is receiving low-dose estrogen. Recommendation of discontinuing all estrogen therapy if a patient develops significant arterial or venous occlusions.

  • Huge study questions HRT's role in heart health. Sibbald, Barbara // CMAJ: Canadian Medical Association Journal;5/30/2000, Vol. 162 Issue 11, p1603 

    Reports the results of a study done by the United States National Institute of Health (NIH) which found that women taking estrogen had more heart attacks, strokes and blood clots than women taking placebos. The number of women in the United States who are taking hormone replacement therapy...

  • Stronger Bones with Less Estrogen Therapy than Usual.  // Tufts University Health & Nutrition Letter;Sep99, Vol. 17 Issue 7, p1 

    Discusses the side effects of hormone replacement therapy (HRT) in the prevention of osteoporosis among postmenopausal women. Effectiveness of less estrogen therapy in preventing the side effects of HRT; Association of breast cancer with HRT; Information on the development of non-hormone drugs...

  • Osteoporosis. Sahley, Billie J. // MMRC Health Educator Reports;2008, p1 

    The article characterizes the symptoms of osteoporosis and suggests various tips to control it. Osteoporosis is characterized by chronic backache, gradual loss of height and stooped posture. It is revealed that calcium alone cannot treat osteoporosis and the pain that comes with it. Estrogen...

  • FDA Fails to Clarify Sarcoma Risk In New Drug-Labeling Change. Napoli, Maryann // HealthFacts;Aug2002, Vol. 27 Issue 8, p3 

    Reports on the decision of the U.S. Food and Drugs Administration to include uterine sarcoma in the written information for consumers of Tamoxifen as one of its side effects.

  • Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Rutquist, Lars E.; Johansson, Hemming // JNCI: Journal of the National Cancer Institute;5/3/95, Vol. 87 Issue 9, p645 

    Assesses the carcinogenic risks associated with long-term use of tamoxifen in women with early stage breast cancer. Determination of incidence of new primary cancers among women participants of the Stockholm Trial; Joint analysis of the incidence of endometrial and gastrointestinal cancers in...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics